Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Atreca Inc chart...

About the Company

atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/

CEO

John Orwin

Exchange

NASDAQ

Website

http://www.atreca.com/

$168M

Total Revenue

101

Employees

$0M

Market Capitalization

-0.03

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BCEL News

Atreca, Inc. (BCEL)

5d ago, source: Yahoo Finance

CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics ...

Atreca, Inc. Class A

4mon ago, source: CNN

Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages ...

Atreca Inc Announces Executive Departures and Consulting Agreements

2mon ago, source: TipRanks on MSN

Atreca Inc (BCEL) has released an update to notify the public and investors about its officers. As Atreca, Inc. scales down ...

Atreca Inc. general counsel sells shares worth $2,645

20d ago, source: Investing

Atreca Inc . (NASDAQ:OTC:BCEL) disclosed a recent stock transaction involving its General Counsel & Secretary, Courtney Phillips, who sold shares to cover tax withholding obligations. The ...

Atreca Inc. Cl A

1mon ago, source: Wall Street Journal

1 Day BCEL -1.11% DJIA -0.06% Russell 2K -0.77% Health Care/Life Sciences -0.38% ...

Atreca, Inc. (BCEL) Latest Stock News & Headlines - Yahoo Finance

6mon ago, source: Yahoo Finance

For example, biotech and... Atreca, Inc. (BCEL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart ...

Atreca, Inc. (BCEL) stock price, news, quote & history – Yahoo Finance

5mon ago, source: Yahoo Finance

CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery ...

Atreca CEO sells shares to cover tax obligations

20d ago, source: Investing

Atreca, Inc. (NASDAQ:OTC:BCEL) President and CEO, John A. Orwin, sold shares worth approximately $8,597 on September 1, 2023, to cover tax withholding obligations associated with the vesting of ...

Atreca Inc Class A

20d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Atreca Inc. general counsel sells shares worth $2,645

20d ago, source: Investing

Atreca Inc . (NASDAQ:OTC:BCEL) disclosed a recent stock transaction involving its General Counsel & Secretary, Courtney Phillips, who sold shares to cover tax withholding obligations. The transaction, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...